HRSA received 200 comments on the Biden administration's proposal to delay until July 20 the effective date of a controversial rule on how much health centers can charge low-income patients for insulin and injectable epinephrine.

FQHCs Fiercely Oppose Trump’s 340B Insulin Pricing Rule in New Round of Comments

Federally qualified health centers and their trade groups are adamantly opposed to implementing a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report